BioCentury on BioBusiness,
HCV doctors: Anemia, payer preference add to sales decline for Vertex's Incivek
Incivek's anemic sales
Monday, November 12, 2012
Pharmaceuticals Inc. maintains
the reasons behind declining sales of HCV drug Incivek telaprevir are due to
marketwide factors, including a bolus of clinical trials and a wait-and-see
attitude by some physicians. But two doctors contacted by BioCentury said
anemia issues specific to Incivek and payer preferences for a competing drug
also play a role.
Regardless of the reasons,
Incivek's best days could be behind it despite entering the market only 18
months ago. Both Incivek and the competing HCV NS3/4A protease inhibitor -
Victrelis boceprevir from Merck
& Co. Inc. - face uncertain
futures as all oral, interferon (IFN)-free regimens are expected to be approved
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]